Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Price

NNNNStock

$3.13−88.71%52W

Market Cap$137.38M

P/E70.33x

PEG Ratio—

Div yield—

Beta2.13

NNNN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-99.05%

Price vs S&P 500 (4W)-43.57%

VGM Score26.65

P/E Ratio (Annual)70.33x

P/CF (Annual)1994.73x

Book Value / Share (Quarterly)$0.21

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-28.39%

Cash Flow / Share (Quarterly)$0.01

Price vs S&P 500 (YTD)-101.52%

Gross Margin (TTM)89.00%

Net Profit Margin (TTM)77.10%

EPS (TTM)$0.23

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$0.23

EPS (Annual)$0.15

ROI (Annual)21.24%

Gross Margin (Annual)87.24%

Net Profit Margin (5Y Avg)47.28%

Cash / Share (Quarterly)$0.08

P/E Basic Excl Extra (TTM)44.15x

Revenue Growth QoQ (YoY)5.64%

P/E Normalized (Annual)70.33x

ROA (Last FY)21.17%

Revenue Growth TTM (YoY)-5.72%

EBITD / Share (TTM)$0.13

ROE (5Y Avg)46.01%

Operating Margin (TTM)69.04%

Cash Flow / Share (Annual)$-0.05

P/B Ratio14.94x

P/B Ratio (Quarterly)143.49x

Net Income / Employee (Annual)$237,200

Net Interest Coverage (TTM)44.91x

ROA (TTM)35.22%

EPS Growth QoQ (YoY)161.32%

EPS Incl Extra (Annual)$0.15

Current Ratio (Annual)344.29x

Quick Ratio (Quarterly)177.11x

3-Month Avg Trading Volume0.12M

52-Week Price Return-88.71%

EV / Free Cash Flow (Annual)1992.16x

P/E Incl Extra (TTM)44.15x

Revenue / Employee (TTM)$490,100

P/S Ratio (Annual)52.09x

Asset Turnover (Annual)0.29x

52-Week High$44.73

Operating Margin (5Y Avg)43.81%

EPS Excl Extra (Annual)$0.15

26-Week Price Return-89.15%

Quick Ratio (Annual)177.12x

13-Week Price Return-67.02%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)344.29x

Enterprise Value$442.61M

Asset Turnover (TTM)0.46x

Revenue / Employee (Annual)$320,300

Pretax Margin (Annual)74.06%

Cash / Share (Annual)$0.08

3-Month Return Std Dev92.09%

Gross Margin (5Y Avg)63.99%

Net Income / Employee (TTM)$377,800

ROE (Last FY)21.24%

EPS Basic Excl Extra (Annual)$0.15

P/FCF (TTM)216.49x

Receivables Turnover (TTM)5.61x

EV / Free Cash Flow (TTM)212.75x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.23

Receivables Turnover (Annual)3.66x

ROI (TTM)35.36%

P/S Ratio (TTM)34.04x

Pretax Margin (5Y Avg)47.28%

Revenue / Share (Annual)$0.20

Price vs S&P 500 (52W)-104.24%

P/E Ratio (TTM)44.15x

EPS Growth TTM (YoY)69.57%

Year-to-Date Return-89.59%

5-Day Price Return-29.02%

EPS Normalized (Annual)$0.15

ROA (5Y Avg)34.25%

Net Profit Margin (Annual)74.06%

Month-to-Date Return-50.32%

EBITD / Share (Annual)$0.13

EPS Growth (3Y)-13.70%

Operating Margin (Annual)66.70%

P/CF (TTM)216.49x

ROI (5Y Avg)46.01%

P/E Excl Extra (TTM)44.15x

EPS Basic Excl Extra (TTM)$0.23

P/B Ratio (Annual)143.49x

Pretax Margin (TTM)77.10%

Book Value / Share (Annual)$0.21

Price vs S&P 500 (13W)-69.70%

Beta2.13x

P/FCF (Annual)216.49x

Revenue / Share (TTM)$0.30

ROE (TTM)35.36%

52-Week Low$3.09

vGradeF

gGradeC

mGradeF

vgmGradeD

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NNNNAnbio Biotechnology Class A Ordinary Shares	F	C	F	34.0x	-5.7%	89.0%	—	$3.13
IDXXIdexx Laboratories Inc	D	B	B	9.7x	12.8%	62.5%	14.3%	$560.36
LNTHLantheus Holdings, Inc	C	B	B	4.2x	2.4%	61.0%	40.7%	$99.70
NEOGNeogen Corp	C	C	A	2.9x	-0.3%	47.4%	—	$11.81
CLDXCelldex Therapeutics, Inc	F	F	C	13683.0x	-97.3%	17.6%	—	$27.53
NTLAIntellia Therapeutics, Inc	D	D	C	26.9x	12.6%	—	—	$11.42
QDELQuidelOrtho Corporation Common Stock	C	C	C	0.3x	-2.5%	44.6%	—	$12.91
ACHVAchieve Life Sciences, Inc.	F	F	B	36.8x	-89.3%	—	—	$6.38
MYGNMyriad Genetics Inc	C	C	D	0.5x	-3.2%	68.8%	—	$3.98
TKNOAlpha Teknova, Inc. Common Stock	D	C	B	8.7x	12.3%	34.6%	—	$7.08
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	59.0x	-60.8%	48.3%	—	$3.01
ICCCImmucell Corp	C	C	A	3.2x	8.5%	40.3%	—	$10.75
BMRABIOMERICA INC	B	D	B	1.9x	-16.2%	8.1%	—	$1.85
TRIBTrinity Biotech plc	B	D	C	0.1x	-16.6%	32.9%	—	$8.03
VNRXVolitionRx Limited	B	B	F	2.0x	86.3%	—	—	$0.18
CDIOCardio Diagnostics Holdings Inc. Common stock	—	D	C	345.9x	-25.9%	—	—	$1.69
QCLSQ/C Technologies, Inc. Common Stock	B	—	F	5.3x	—	24.7%	—	$0.54
VRAXVirax Biolabs Group Limited Ordinary Shares	—	B	F	156.9x	96.4%	62.0%	—	$1.45
CDIOWCardio Diagnostics Holdings Inc. Warrant	—	—	F	—	—	—	—	$0.01

About Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is an in vitro diagnostics company offering laboratory, point-of-care, and at-home testing solutions across infectious diseases, oncology, cardiovascular health, and other clinical domains. Its product portfolio includes automated analyzers such as the AF-1200 fluorescence immunoassay and SHA-100 dry chemistry systems, along with rapid diagnostic kits for conditions including COVID-19, dengue, and hepatitis. The company generates revenue primarily from Europe, with significant presence in South America and Asia-Pacific.